NASDAQ:IBB iShares Biotechnology ETF (IBB) Price, Holdings, & News $167.46 +3.27 (+1.99%) As of 02:15 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsSEC FilingsShort InterestTrendsBuy This Stock About iShares Biotechnology ETF (NASDAQ:IBB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IBB alerts:Sign Up Key Stats Today's Range$165.08▼$167.6350-Day Range$160.41▼$176.6652-Week Range$119.78▼$179.64Volume821,569 shsAverage Volume1.70 million shsMarket Capitalization$7.78 billionAssets Under Management$7.64 billionDividend Yield0.23%Net Expense Ratio0.45%Aggregate RatingModerate Buy ETF Overview iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc. Read More iShares Biotechnology ETF ExpensesTypeIBBHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.45%0.56%0.57%0.54%0.53%Other Expenses0.00%0.47%0.55%0.51%0.55%Total Expense0.45%0.74%0.76%0.73%0.73%Fee Waiver0.00%-0.71%-0.64%-0.50%-0.62%Net Expense0.45%0.59%0.63%0.62%0.60% Receive IBB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IBB ETF News HeadlinesBiotech Investors Are Tuning Out the MAHA ChaosMay 20 at 5:30 AM | wsj.com2 Ways to Play the Big Pharma Patent Cliff (IBB)With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.May 14, 2026 | marketbeat.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 20 at 1:00 AM | Profits Run (Ad)Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position NowApril 23, 2026 | 247wallst.comXBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026April 7, 2026 | 247wallst.comBiotech Stocks Are Up About 35% in the Past Year and Analysts Say the Biggest Gains Are Still AheadMarch 28, 2026 | 247wallst.comSee More Headlines IBB ETF - Frequently Asked Questions How have IBB shares performed this year? iShares Biotechnology ETF's stock was trading at $168.77 at the start of the year. Since then, IBB shares have decreased by 1.1% and is now trading at $166.96. When did iShares Biotechnology ETF's stock split? Shares of iShares Biotechnology ETF split on Friday, December 1st 2017.The 3-1 split was announced on Tuesday, November 7th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, November 30th 2017. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. Who are iShares Biotechnology ETF's major shareholders? iShares Biotechnology ETF's top institutional shareholders include Bank of America Corp DE (15.28%), Royal Bank of Canada (1.57%), Janney Montgomery Scott LLC (1.33%) and PNC Financial Services Group Inc. (0.67%). How do I buy shares of iShares Biotechnology ETF? Shares of IBB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iShares Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that iShares Biotechnology ETF investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Fund Details IssueriShares Fund NameiShares Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:IBB Inception Date2/5/2001 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNYSE Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings255 Fund Statistics Assets Under Management$7.64 billion Average Daily Volume$1.44 million Discount/Premium-0.03% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Chase Bank, N.A. AdvisorBlackRock Fund Advisors CustodianJPMorgan Chase Bank, N.A. DistributorBlackRock Investments, LLC Transfer AgentJ.P. Morgan Chase Bank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableOptionable Options Volume254 Put Options189 Call Options65 Short Interest13,270,000 shs Miscellaneous Outstanding Shares46,450,000Beta0.73 Creation Unit50,000 Creation Fee$614.00 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report Top 10 IBB HoldingsVertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 7.52%Gilead Sciences (NASDAQ:GILD)Holding Weight: 7.36%Amgen (NASDAQ:AMGN)Holding Weight: 7.19%Regeneron Pharmaceuticals (NASDAQ:REGN)Holding Weight: 6.67%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 3.54%argenex (NASDAQ:ARGX)Holding Weight: 3.46%Biogen (NASDAQ:BIIB)Holding Weight: 2.57%Natera (NASDAQ:NTRA)Holding Weight: 2.38%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 2.37%Insmed (NASDAQ:INSM)Holding Weight: 2.26%Full Holdings DetailsIBB Sector ExposureIBB Industry Exposure This page (NASDAQ:IBB) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredSaudi Arabia just broke its 50-year dollar arrangementSaudi Arabia has quietly walked away from its 1974 petrodollar agreement with the U.S. - the pact that require...Golden Portfolio | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredForget SpaceX. Buy the company Musk can't replace.The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks an...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share iShares Biotechnology ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
